Fahri Küçükali,Elizabeth Hill,Tijs Watzeels,Holger Hummerich,Tracy Campbell,Lee Darwent,Steven Collins,Christiane Stehmann,Gabor G Kovacs,Michael D Geschwind,Karl Frontzek,Herbert Budka,Ellen Gelpi,Adriano AA Aguzzi,Sven J van der Lee,Cornelia M van Duijn,Pawel P Liberski,Miguel Calero,Pascual Sanchez-Juan,Elodie Bouaziz-Amar,Jean-Louis Laplanche,Stéphane Haïk,Jean-Phillipe Brandel,Angela Mammana,Sabina Capellari,Anna Poleggi,Anna Ladogana,Maurizio Pocchiari,Saima Zafar,Stephanie Booth,Gerard H Jansen,Aušrinė Areškevičiūtė,Eva Løbner Lund,Katie Glisic,Piero Parchi,Peter Hermann,Inga Zerr,Jiri Safar,Pierluigi Gambetti,Brian S Appleby,John Collinge,Kristel Sleegers,Simon H Mead

Abstract:Prions are misfolded prion protein assemblies that cause several fatal and transmissible neurodegenerative diseases, with the most common phenotype in humans being sporadic Creutzfeldt-Jakob disease (sCJD). However, aside from the prion protein itself, molecular risk factors are not well understood. Prion and prion-like mechanisms are thought to underpin common neurodegenerative disorders meaning that the elucidation of mechanisms could have broad relevance. Herein we sought to further develop our understanding of the factors that confer risk of sCJD using a systematic gene prioritization and functional interpretation pipeline based on multiomic integrative analyses. We integrated the published sCJD genome-wide association study (GWAS) summary statistics with publicly available bulk brain and brain cell type gene and protein expression datasets. We performed multiple transcriptome and proteome-wide association studies (TWAS & PWAS) and Bayesian genetic colocalization analyses (coloc) between sCJD risk association signals and multiple brain molecular quantitative trait loci (QTL) signals. We then applied our systematic gene prioritization pipeline on the obtained results and nominated prioritized sCJD risk genes with risk-associated molecular mechanisms in a transcriptome and proteome-wide manner. Genetic upregulation of both gene and protein expression of syntaxin-6 ( ) in the brain was associated with sCJD risk in multiple datasets, with a risk-associated gene expression regulation specific to oligodendrocytes. Similarly, increased gene and protein expression of protein disulfide isomerase family A member 4 ( ), involved in the unfolded protein response, was linked to increased disease risk, particularly in excitatory neurons. Protein expression of mesencephalic astrocyte derived neurotrophic factor ( ), involved in protection against endoplasmic reticulum stress and sulfatide binding (linking to the enzyme in the final step of sulfatide synthesis, encoded by sCJD risk gene ), was identified as protective against sCJD. In total 32 genes were prioritized into two tiers based on level of evidence and confidence for further studies. This study provides insights into the genetically-associated molecular mechanisms underlying sCJD susceptibility and prioritizes several specific hypotheses for exploration beyond the prion protein itself and beyond the previously highlighted sCJD risk loci through the newly prioritized sCJD risk genes and mechanisms. These findings highlight the importance of glial cells, sulfatides and the excitatory neuron unfolded protein response in sCJD pathogenesis.

The role of microglia in prion diseases and possible therapeutic targets: a literature review

Brain microglia were activated in sporadic CJD but almost unchanged in fatal familial insomnia and G114V genetic CJD

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

Interactions between Cytokines and the Pathogenesis of Prion Diseases: Insights and Implications

Engulfment of viable neurons by reactive microglia in prion diseases

Novel Morphological Glial Alterations in the Spectrum of Prion Disease Types: A Focus on Common Findings

Reactive microglia partially envelop viable neurons in prion diseases

Activation of Innate Immunity and Autophagy in Brain Tissues with Prion Disease and Degradation of Abnormal PrPs in Cells — China’s Studies

Neuroinflammation, Microglia, and Cell-Association during Prion Disease

The Role of Glial Cells in Neurobiology and Prion Neuropathology

Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances

The importance of ongoing international surveillance for Creutzfeldt–Jakob disease

MicroRNAs in Prion Diseases-From Molecular Mechanisms to Insights in Translational Medicine

Multiomic Analyses Direct Hypotheses for Creutzfeldt-Jakob Disease Risk Genes

Microglia-specific NF-κB signaling is a critical regulator of prion-induced glial inflammation and neuronal loss

Supportive care or exhausted neglect: the role of microglia at the end stage of prion disease

New implications for prion diseases therapy and prophylaxis

Expression of excitatory amino acid transporter-1 (EAAT-1) in brain macrophages and microglia of patients with prion diseases

Therapeutic perspectives for prion diseases in humans and animals

Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease

PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldt–Jakob Disease